Patients with suspected multiple myeloma should be investigated with screening tests. They may have a paraprotein in the serum, Bence-Jones protein in the urine, or both. If these proteins are detected by a protein electrophoretogram, the patient requires further investigation to distinguish multiple myeloma from monoclonal gammopathy of uncertain significance. Identifying the paraprotein isotype assists in the diagnosis of multiple myeloma, but bone marrow biopsy is needed to show the percentage of plasma cells in the marrow.
Introduction

Initial investigations
Patients suspected of having multiple myeloma first have screening tests and then more specialised tests to confirm the diagnosis. This sequence of investigations identifies the presence of a clonal plasma cell disorder, then differentiates whether it is behaving benignly (monoclonal gammopathy of uncertain significance) or malignantly (multiple myeloma) (Fig. 1) .
The basic tests include a full blood count, urea, creatinine, and electrolytes including calcium. All patients are screened with electrophoresis of serum and urine. 
Serum and urine protein electrophoresis
Serum immunoglobulin quantitation
Measuring total concentrations of IgG, IgA and IgM in serum can reveal elevation of a specific immunoglobulin isotype that is suggestive of the presence of a paraprotein. However, the test does not distinguish between the normal polyclonal and abnormal monoclonal forms of a particular immunoglobulin. 
Erythrocyte sedimentation rate
The erythrocyte sedimentation rate (ESR) was used in screening for myeloma before the ready availability of serum and urine protein electrophoresis. Very high values are often observed in association with a serum paraprotein, but there are many other causes of a very high ESR and it therefore lacks specificity.
Another limitation is that typically the ESR is not significantly elevated in Bence-Jones myeloma. Transformation in a patient with an IgM paraprotein is usually to lymphoproliferative malignancy, while in patients with an IgA or IgG paraprotein the transformation is usually to myeloma. 1 The detection of a paraprotein is often an incidental finding and insufficient to confirm a diagnosis of myeloma. Further information is required to establish whether the paraprotein disorder is monoclonal gammopathy of uncertain significance or myeloma. 
Differentiation of monoclonal gammopathy of uncertain significance from multiple myeloma
Fig. 1
Screening and diagnosis of multiple myeloma
Skeletal radiology
A major distinction between myeloma and monoclonal gammopathy of uncertain significance is increased lysis of bone resulting from the activation of osteoclasts by myeloma cells. In myeloma a skeletal X-ray survey commonly reveals abnormalities such as multiple, discrete lytic lesions, vertebral crush fractures, or even areas of diffusely reduced bone density.
These findings are some of the most important means for detecting the malignant characteristics of myeloma.
Bone scan
Conventional bone scanning with technetium-99 labelled methylene diphosphonate measures localisation of the tracer in many tissues, including newly formed bone due to increased osteoblastic activity. The tracer is not selectively accumulated by myeloma tissue. While there may be quiescent osteoblast activity in myeloma, increased osteoblastic activity also occurs at sites of repair after fracture and sites affected by infection or inflammation. Bone scanning therefore lacks specificity for myeloma and is not a suitable alternative to radiological examination.
Bone marrow examination
A bone marrow aspirate and trephine biopsy is a key procedure 
Conclusion
Multiple myeloma causes widely varied clinical manifestations.
Early diagnosis will lead to the correct management. Screening tests to detect paraproteins are followed by biopsy to confirm the increased presence of plasma cells in the bone marrow.
